Big pharma's contingency for expiring patents: How top global pharmaceutical firms are reinventing themselves to cope with major upcoming challenges
For years, big pharma has braced itself for an impending patent cliff – when patents expire, so does market exclusivity and resulting in an abrupt drop in sales. And with few new “blockbusters” – drugs with annual sales of more than US$1bil (RM3.56bil) each – in the pipeline, it is no wonder the industry has been scrambling to reinvent itself.
Already a subscriber? Log in
The Star 6.6 DEAL: 35% OFF Digital Access
Cancel anytime. Ad-free. Unlimited access with perks.
